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Abstract
Background: Vascular endothelial cells (ECs) are a target of antibody-mediated allograft rejection. In vitro, when the HLA
class I molecules on the surface of ECs are ligated by anti-HLA class I antibodies, cell proliferation and survival pathways are
activated and this is thought to contribute to the development of antibody-mediated rejection. Crosslinking of HLA class I
molecules by anti-HLA antibodies also triggers reorganization of the cytoskeleton, which induces the formation of F-actin
stress fibers. HLA class I induced stress fiber formation is not well understood.
Methodology and Principal Findings: The present study examines the protein composition of the cytoskeleton fraction of
ECs treated with HLA class I antibodies and compares it to other agonists known to induce alterations of the cytoskeleton in
endothelial cells. Analysis by tandem mass spectrometry revealed unique cytoskeleton proteomes for each treatment
group. Using annotation tools a candidate list was created that revealed 12 proteins, which were unique to the HLA class I
stimulated group. Eleven of the candidate proteins were phosphoproteins and exploration of their predicted kinases
provided clues as to how these proteins may contribute to the understanding of HLA class I induced antibody-mediated
rejection. Three of the candidates, eukaryotic initiation factor 4A1 (eIF4A1), Tropomyosin alpha 4-chain (TPM4) and DDX3X,
were further characterized by Western blot and found to be associated with the cytoskeleton. Confocal microscopy analysis
showed that class I ligation stimulated increased eIF4A1 co-localization with F-actin and paxillin.
Conclusions/Significance: Colocalization of eIF4A1 with F-actin and paxillin following HLA class I ligation suggests that this
candidate protein could be a target for understanding the mechanism(s) of class I mediated antibody-mediated rejection.
This proteomic approach for analyzing the cytoskeleton of ECs can be applied to other agonists and various cells types as a
method for uncovering novel regulators of cytoskeleton changes.
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Introduction
The composition of the eukaryotic cytoskeleton consists mainly
of three discrete fibrous structures—actin microfilaments, micro-
tubules and intermediate filaments. These structures provide the
framework to maintain cell shape and polarity and also contribute
to other fundamental cellular functions such as motility, organelle
transport and division [1]. These cellular processes are carried out
through the actions of multiple molecules, which comprise
functional modules [2]. These interactions can been seen in
cryoelectron tomography images, in which functional modules
appear to be spatially congested while at the same time highly
organized [3,4]. It has been suggested that an intact actin
cytoskeleton is fundamentally responsible for the functional
organization within the cell [5].
In ECs, the cytoskeleton plays an essential role in providing a
sturdy intracellular scaffold, which serves to organize vital
membrane proteins within the cell. The cytoskeleton also has
the ability to respond to extracellular stimuli and undergo
reorganization [6]. Additionally, several lines of evidence support
the notion that numerous soluble proteins can be associated with
the cytoskeleton [5]. These findings boost the role of the
cytoskeleton, as not only the defining structure of the cell, but
also as a key regulator of the intracellular environment [7].
When ECs are quiescent, actin creates a cortical ring providing
a link between cell-cell and cell-matrix adhesion complexes and
intracellular organelles. The cortical actin ring is necessary to
sustain the EC barrier function [8] and its disruption can initiate
EC permeability [9]. When ECs are stimulated with inflammatory
agonists such as thrombin and histamine, the cortical actin ring is
reorganized in such a manner that stress fibers are created, which
extend throughout the cell [10].
Understanding how ECs respond to stimuli that mediate
cytoskeleton changes is an important topic in organ allograft
rejection. Antibodies directed toward HLA class I molecules on
the donor endothelium play a major role in antibody-mediated
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events that occur in EC following the binding of HLA class I
antibodies contribute to the process of chronic rejection and
transplant vasculopathy. Signaling through the HLA class I
molecules on the surface of ECs is associated with changes in
the actin cytoskeleton. HLA class I ligation on ECs activates the
GTP binding protein RhoA [12] and utilizes Rho GTPase and
Rho-kinase (ROK) to promote stress fiber formation [13]. In
addition, HLA class I ligation activates Src, focal adhesion kinase
(FAK), and paxillin [14]. FAK is central regulator of this signaling
cascade as it is critical for focal adhesion assembly and stress fiber
formation [15]. These signaling cascades represent early events
leading to activation of downstream pathways in the endothelium
that can be detrimental to graft survival. One such pathway is the
proliferation pathway. The mammalian target of rapamycin
(mTOR) is an essential regulator of cell proliferation and protein
synthesis through the activation of p70 ribosomal S6 kinase (S6K)
and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1)
[16,17]. Ligation of HLA class I molecules on the surface of ECs
promotes proliferation via the mTOR pathway [18]. Understand-
ing how cytoskeleton changes contribute to these signaling
cascades will advance our understanding of EC proliferation,
migration and permeability, all of which may contribute to the
mechanism(s) underlying antibody-mediated transplant rejection.
Here we present the results of a proteomic-based analysis
characterizing changes in the cytoskeleton of human aortic ECs
following stimulation with thrombin, basic fibroblast growth factor
and HLA class I antibodies. The contents of these isolations were
characterized by mass spectrometry, annotated and a candidate
list of HLA class I-induced cytoskeleton associated proteins was
identified. Three of the candidates, TPM4, eIF4A1 and DDX3X,
were further characterized. TPM4 was uniquely found in the
cytoskeletal fraction of class I stimulated ECs, but absent in the
cytoskeleton of ECs stimulated with thrombin and bFGF. The
eIF4A1 protein, a regulator of protein synthesis and cell
proliferation, was found in association with the actin cytoskeleton
by Western blot and showed a higher degree of colocalization with
F-actin and paxillin in HLA class I stimulated cells compared to
the other treatment groups. This proteomic discovery approach
provides candidate targets, which may link HLA class I-induced




Informed written consent for use of the aortic tissue as an
anatomical gift for research was obtained by OneLegacy (a
federally-designated organ procurement organization) at the time
of organ donation from the next of kin or authorized party. The
use of the human aortic tissue for the research described herein
was approved by the OneLegacy Biomedical Review Board under
the agreement #RS-02-10-2 and UCLA MTA2009-561.
Antibodies and Chemicals
Cytochalasin D was purchased from Sigma-Aldrich. Recombi-
nant human bFGF was purchased from R&D Systems. Human a-
thrombin was from Enzyme Research Laboratories. The murine
monoclonal antibody W6/32 (IgG2a), reactive with a monomor-
phic epitope on HLA class I antigens, was obtained from the
American Type Culture Collection. The mouse IgG used as an
isotype control was supplied by Sigma-Aldrich. Recombinant
human FGF basic was from R&D Systems. Antibodies used for
Western blot were b-actin, eIF4A1, 4E-BP1 obtained from Cell
Signaling and vinculin, b-tubulin, and myosin light chain (all three
from Santa Cruz) and b1-integrin and paxillin (BD Biosciences)
and TPM4 and DDX3X (both from Acris Antibodies). The
eIF4A1 antibody used for confocal microscopy was obtained from
Santa Cruz. A second eIF4A1 antibody obtained from Abcam was
used to confirm the specificity of the immunofluorescent staining
pattern. The fluoresent conjugated secondary antibodies, Alexa-
fluor 488 goat anti-rabbit, Rhodamine Red
TM-X goat anti-mouse
and Texas Red-phalloidin were from Invitrogen.
Cell Culture
Primary human aortic ECs were isolated from the aortic rings of
explanted donor hearts, as previously described [19]. ECs were
cultured in M199 complete medium composed of sodium pyruvate
(1 mM) (Irvine Scientific), penicillin (100 U/mL) and streptomycin
(100 mg/ml) (both from Invitrogen), 20% (v/v) FBS (HyClone),
heparin (90 mg/ml) (Sigma-Aldrich), and endothelial cell growth
supplement (20 mg/ml) (Fisher Scientific). Cells from passages 4–
10 were used at 80%–90% confluence.
F-actin Staining
ECs grown to 80–90% were starved for 2 h in basal medium
containing 0.2% FBS followed by treatment with mAb W6/32
(1 mg/ml) (referred to as HLA class I stimulated), isotype control
mouse IgG (1 mg/ml) (referred to as unstimulated), thrombin
(1 U/ml) or bFGF (25 ng/ml) for 10 min. Treated ECs were fixed
with 4% paraformaldehyde and permeabilized with 0.2% Triton-
X-100. The presence of F-actin was visualized by direct staining
with Texas Red–phalloidin. Cells were analyzed with Zeiss
Axioplan 2 microscope with the Zeiss FluoArc 100 watt mercury
light source. Digital images of fluorescence were obtained with a
cooled charge-coupled device camera (SPOT 2, Diagnostic
Instruments) and associated software (SPOT 4.5, Diagnostic
Instruments).
Cytoskeleton Isolation
The method was adapted from a previously published method
[7]. Prior to use in experiments, ECs were grown for 16 h in
medium containing 0.2% FBS. ECs were treated with mAb W6/
32 (1 mg/ml), mouse isotype control IgG (1 mg/ml), thrombin
(1 U/ml) or bFGF (25 ng/ml) for 10 min at 37uC, washed once
with ice-cold PBS and lysed in buffer containing (20 mM Tris
(pH 7.9), 137 mM NaCl, 5 mM EDTA, 1 mM EGTA, 10%
glycerol, 1% Triton X-100, 10 mM NaF, 1 mM PMSF, 1 mM
Na3VO4, 10 mg/ml aprotinin, and 10 mg/ml leupeptin) for
10 min on ice. The samples were sonicated for 30 sec.
Tosylactivated Dynal-beads M280 (50 ml/sample) (Invitrogen)
were first pre-blocked using a blocking buffer (0.5 M Tris, 1 M
glycine). Next the beads were washed once with PBS. The lysate
was then added to the beads and the mixture incubated on ice for
15 min with intermittent mixing. The beads were collected by a
magnetic particle concentrator (MPC) (Dynal) and washed 2 times
with PBS and 2 times with 10 mM Tris-HCl pH 8.
Western Blot
Beads containing the cytoskeleton isolation preparations were
heated for 5 min at 95uC in SDS sample buffer, electrophoresed
on SDS polyacrylamide gels, and transferred to a polyvinylidene
difluoride membrane. The membranes were blocked using 5%
nonfat dry milk in TBS (pH 7.4) containing 0.1% Tween 20
(TBST) for 20 min at room temperature, and incubated with the
appropriate primary antibody overnight at 4uC. The blots were
washed with TBST followed by incubation in HRP-conjugated
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temperature. The blots were subsequently washed with TBST and
developed with ECL.
In-Solution Tryptic Digestion
Beads containing the cytoskeleton proteins were resuspended in
digestion buffer (50 mM ammonium bicarbonate). The sample
was first reduced using 100 mM DTT (Sigma-Aldrich). Next, the
preparation was alkylated using 100 mM iodoacetamide (Sigma
Aldrich). The proteins were then digested overnight using
proteomics grade trypsin (Sigma Aldrich) at a concentration of
0.1 mg/ml. Following trypsin digest, the beads were centrifuged at
14,0006g for 1 min and the supernatant was collected.
Peptide Purification
Magnetic Dynabeads RPC 18 (Invitrogen) were used to bind
the cytoskeleton peptides for purification. RPC 18 beads were first
washed with binding buffer (0.1% TFA/0.5%ACN). The
cytoskeleton peptides were mixed with binding buffer then added
to the beads. The beads were washed 4 times with binding buffer
and eluted with 60% ACN.
Nano-liquid chromatography with tandem mass
spectrometry (nLC-MSMS)
nLC-MS/MS with Collision Induced Dissociation (CID) is
performed on a 7 tesla LTQ FT Ultra (Thermo Scientific,
Waltham, MA) integrated with an Eksigent nano-LC. A prepacked
reverse-phase column (Microtech Scientific C18 with a dimension
of 100 mm63.5 cm) containing reverse-phase resin (Biobasic C18,
5-mm particle size, 300-A ˚ pore size, Microtech Scientific, Fontana,
CA) is used for peptide chromatography and subsequent CID
analyses. ESI conditions using the nano-spray source (Thermo
Fisher) for the LTQ-FT are set as follows: capillary temperature of
220uC, tube lens 110 V and a spray voltage of 2.5 kV. The flow
rate for reverse-phase chromatography is 5 ml/min for loading and
300 nl/min for the analytical separation (buffer A: 0.1% formic
acid, 1% ACN; buffer B: 0.1% formic acid, 100% ACN). Peptides
are resolved by the following gradient: 2–60% buffer B over
40 min, then increased to 80% buffer B over 10 min and then
returned to 0% buffer B for equilibration of 10 min. The LTQ FT
is operated in data-dependent mode with a full precursor scan at
high-resolution (100000 at m/z 400) and six MSMS experiments
at low resolution on the linear trap while the full scan is completed.
For CID the intensity threshold was set to 5000, where mass range
was 350–2000. Spectra are searched using Mascot software
(Matrix Science, UK) in which results with p,0.05 (95%
confidence interval) were considered significant and indicating
identity. The data was also analyzed through Sequest database
search algorithm implemented in Discoverer software (Thermo
Fisher, Waltham, MA).
Confocal Microscopy
ECs were grown on 35 mm glass bottom dishes to 80–90%
confluence and starved for 2 h in basal medium containing 0.2%
FBS followed by treatment with mAb W6/32 (1 mg/ml), isotype
control mouse IgG (1 mg/ml), thrombin (1 U/ml) or bFGF
(25 ng/ml) for 10 min. Treated ECs were fixed with 4%
paraformaldehyde and permeabilized with 0.2% Triton-X-100.
Cells were incubated with primary antibody (mouse anti-paxillin
or rabbit anti- eIF4A1) in 5% BSA in PBS overnight at 4uC
washed and incubated with secondary antibody (Alexafluor 488
goat anti-rabbit for eIF4A1 and Rhodamine Red
TM-X goat anti-
mouse IgG for paxillin) for 30 min at room temperature. The
presence of F-actin was visualized by direct staining with Texas
Red–phalloidin. Cell images were captured using a Zeiss LSM 510
confocal microscope at 636magnification using the Zeiss LSM 5
PASCAL software (Carl Zeiss MicroImaging GmbH, Germany)
Results
HLA class I ligation induces stress fiber formation
A comparison of F-actin reorganization by immunofluorescence
revealed that stimulation with HLA class I antibodies (Fig. 1B) or
thrombin (Fig. 1C) activated stress fiber formation, while bFGF
(Fig. 1D) failed to produce stress fibers. Stimulation of ECs with an
antibody to HLA class I showed an 86% increase in the mean
fluorescence intensity of F-actin staining (p=5E-07). Thrombin
stimulation also significantly increased the mean fluorescence
intensity of F-actin staining by 139% (p=2E-09), whereas
stimulation with bFGF decreased F-actin staining by 11%
compared to the unstimulated cells (Fig. 1E). Although both
thrombin and HLA class I antibodies triggered actin remodeling,
the HLA class I antibody-induced stress fiber response was weaker
than that induced by thrombin (Fig. 1C vs 1B). We examined the
effects of low and high doses of thrombin and compared it to the
signaling pathways elicited by anti-HLA class I antibodies (MZ
unpublished data). Stimulation with thrombin at high concentra-
tions (1 U/ml) induced a robust increase in the intracellular Ca
2+
concentration and promoted stress fiber formation in an ERK-
independent manner. In contrast, stimulation of ECs with either
HLA class I antibodies or a low dose of thrombin (1 mU/ml) did
not promote any detectable change in intracellular Ca
2+
concentration, but induced myosin light chain (MLC) phosphor-
ylation and stress fiber assembly via MLC kinase (MLCK) and
ROK in an ERK1/2-dependent manner. Thus, the pathway
activated by the high dose of thrombin is different from the
pathway activated by a lower dose of thrombin and HLA class I
ligation. Given these observations, we hypothesized that the
isolation and proteomic characterization of the cytoskeletal
proteins in HLA class I stimulated ECs could lead to a better
understanding of the mechanisms underlying HLA class I induced
stress fibers.
The EC cytoskeleton can be isolated
Previous studies showed that the cytoskeleton and its associated
proteins could be selectively enriched using Dynal beads [7]. The
cytoskeleton was isolated from unstimulated ECs and ECs
stimulated with an HLA class I antibody, thrombin or bFGF.
For the following Western blot experiments, ECs were also treated
with a cytochalasin D followed by cytoskeleton isolation. Western
blot analysis revealed that when an intact cytoskeleton was isolated
from ECs, the cytoskeleton proteins vinculin, ß-tubulin, MLC and
ß-actin were detected, while disruption of the cytoskeleton with
cytochalasin D prevented the isolation of these proteins
(Figure 2A). Previous studies demonstrated that the absence of
ß1 integrin in the cytoskeleton fraction marks the selective
enrichment of the cytoskeleton and its associated proteins [7,20].
When the cytoskeleton was isolated from ECs, the ß1 chain of
integrin was only detected in the cytoskeleton-depleted fraction
and was not found in the cytoskeleton-enriched fraction
(Figure 2B).
Identification of cytoskeleton associated proteins
Using in-solution trypsin digestion the isolated cytoskeleton
fraction from each treatment group was digested into peptides. To
identify the proteins in the cytoskeleton isolation preparations,
nLC-MS/MS was performed on the peptides and Mascot searches
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group is summarized in Table S1. A total of 128 cytoskeleton-
associated proteins were identified in unstimulated ECs, 126 in
HLA class I stimulated ECs, 67 in thrombin treated ECs and 88 in
bFGF treated ECs. When these proteins were compared between
the treatment groups we identified 62 unique proteins in the
unstimulated group, 56 in the HLA class I group, 10 in the
thrombin group and 20 in the bFGF group.
Classification of the cytoskeleton proteins
The identified proteins were classified using the Gene Ontology
(GO) enrichment analysis tool Gene Onology Tree Machine
(GOTM) [21]. The results are represented as a directed acyclic
graph (DAG) in order to preserve the relationships among the
enriched GO categories. For each treatment group, a DAG was
produced and certain GO categories were significantly enriched in
each data set. Figure 3 is a re-creation of the DAG generated by
GOTM for the HLA class I stimulated group. The grey boxes are
categories that were not significantly enriched, while the
significantly enriched categories found in the HLA class I treated
group are shown by the white boxes and include the adjusted p-
values (using Benjamini Hochberg) and the number of proteins
found in each category. The significantly enriched categories in
the HLA class I treated group were compared to the other
treatment groups and if the categories in the class I group were
also enriched in any of the other treatment groups then these
categories were not considered a unique category of HLA class I
unique cytoskeleton changes. The categories found to be uniquely
enriched by HLA class I stimulation are indicated by the bold-
faced boxes (Fig. 3).
To determine which proteins are important for inducing HLA
class I cytoskeleton changes, the proteins found under the unique
categories of the HLA class I DAG were examined (Fig. 3, bold-
faced boxes). Using this list of proteins in the HLA class I group,
Figure 1. Comparison of HLA class I stimulated EC cytoskeleton changes with other agonists. Human aortic ECs were treated with either
mIgG 1 mg/ml (A), HLA class I antibody (Ab) 1 mg/ml (B), thrombin 1 U/ml (C) or bFGF 25 ng/ml (D) for 10 min. Cells were stained with Texas-Red–
phalloidin and analyzed by fluorescence microscopy. (E) The fluorescence intensity and the total area of each cell in each field were measured using
ImageJ software (http://rsb.info.nih.gov/ij/). Three independent experiments were performed and in each experiment 3 fields were measured. The
ratio between the mean fluorescence intensity and the cell area was calculated to account for changes in cell shape due to contraction. The data was
normalized to the mIgG group and the others groups were calculated to reflect the change compared to the mIgG group. A student’s t-test was
performed to determine significant changes between the groups, P,0.05.
doi:10.1371/journal.pone.0029472.g001
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thrombin and bFGF treated cells (Table S1). If a protein found
under the HLA class I unique category was also found in any of
the other treatment groups it was not considered a candidate
protein. After eliminating the proteins that were also found in the
other treatments groups, 12 candidate proteins were identified
(Table 1).
Prediction of protein kinases
Among the 12 candidates identified, 11 of the proteins were
phosphoproteins with the exception of RCF4 (Table 1). The 11
candidate phosphoprotein sequences and their corresponding
phosphorylation sites were submitted to the online-software
NetworKIN-2.0, which provides a list of kinase predictions and
grants insight into the interaction networks between phosphopro-
teins and kinase families based on the latest human phosphopro-
teome [22]. Using the known phosphorylation sites of the 11
candidate phosphoproteins it was determined that 35 kinase
families could be responsible for their activation and among these
35 families there were 70 individual kinases (Table 2).
To determine the role these kinases may play in HLA class I
cytoskeleton activation the 70 protein kinases were annotated
using GOanna [23] and the GO terms were then categorized
using CateGOrizer [24]. The top three GO categories represented
by the 70 kinases were cell communication (26%), metabolism
(14%) and signal transduction (11%) (Fig. 4).
Validation of protein candidates
To confirm the presence of the candidate proteins in the
cytoskeleton fraction, we performed Western blot experiments
with antibodies to 3 of these candidate proteins, DDX3X, TPM4
and eIF4A1 (Table 1). MLC, a well documented component of the
actin cytoskeleton, was found in the cytoskeleton fraction of all
treatment groups, but absent in the cytoskeleton fractions
following treatment with cytochalasin D (Fig. 5A). Similarly, all
4 treatment groups showed DDX3X in the cytoskeleton fraction,
but not when the cytoskeleton was disrupted using cytochalasin D.
TPM4 was only found in the cytoskeleton fraction of ECs treated
with anti-HLA class I antibodies and its association with the
cytoskeleton was abrogated by pretreatment with cytochalasin D
(Fig. 5A).
Among the list of candidates, eIF4A1 was selected for further
characterization because it functions as a downstream target of
mammalian target of rapamycin (mTOR) [25] and we previously
reported a role for mTOR in class I-mediated cell proliferation
[18]. The cytoskeleton isolation was repeated for each treatment
group, and various proteins in the cytoskeleton fraction were
compared to the total cell lysate and the depleted fraction of the
cytoskeleton by Western blot. As expected, the known cytoskeleton
components, ß-actin and MLC, were found in the cytoskeleton
fraction (Fig. 5B). eIF4A1 was also found in the cytoskeleton
fraction of all treatment groups (Fig. 5B). However, eIF4A1 was no
longer captured in the cytoskeleton fraction following treatment
with cytochalasin D. These data demonstrate that capture of the
total cytoskeleton contains eIF4A1 in all 4 of the treatment
conditions when examined by Western blot.
We next examined HLA class I-induced eIF4A1 interactions
with the cytoskeleton by performing cellular colocalization studies.
For this, confocal microscopy was performed to determine the
degree of colocalization of eIF4A1 with F-actin and paxillin, both
Figure 2. Validation of the EC cytoskeleton isolation by Western blot. (A) Human aortic ECs were treated for 10 min with either mIgG 1 mg/
ml (lane 1), HLA class I Ab 1 mg/ml (lane 2), thrombin 1 U/ml (lane 3), bFGF 25 ng/ml (lane 4) or treated with cytochalasin D 5 mM (lane 5) for 30 min.
The cytoskeleton was isolated from the lysates using tosylactived magnet Dynal beads and the fraction was analyzed by Western blot for
components of the cytoskeleton. (B) Human aortic ECs were treated for 10 min with either mIgG 1 mg/ml (lanes 1 and 6), HLA class I Ab 1 mg/ml
(lanes 2 and 7), thrombin 1 U/ml (lanes 3 and 8), bFGF 25 ng/ml (lanes 4 and 9) or treated with cytochalasin D 5 mM (lanes 5 and 10) for 30 min. The
cytoskeleton was isolated using tosylactived magnetic Dynal beads. The cytoskeleton fraction (lanes 6–10) and the depleted fraction after
cytoskeleton isolation (lanes 1–5) were immunoblotted to detect the presence of ß1-integrin and ß-actin as a loading control. The data presented in
panels A and B are representative of 5 independent experiments.
doi:10.1371/journal.pone.0029472.g002
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[14]. Figure 6A shows the localization of eIF4A1 and F-actin in
the ECs. The colocalization image (Fig. 6B) generated by the
ImageJ plugin was used to calculate changes in the level of
colocalization (Fig. 6C). The eIF4A1 protein aligned with F-actin
stress fibers in both the HLA class I and thrombin stimulated ECs.
The degree of colocalization was more prominent in ECs treated
with HLA class I antibodies compared to thrombin treated ECs,
but this difference did not reach statistical significance (p=0.07).
The colocalization intensity of eIF4A1 and F-actin following HLA
class I stimulation was statistically significant when compared to
the unstimulated (p=0.006) and bFGF treated groups (p=0.002).
To assess the specificity of the association between eIF4A1 and the
actin cytoskeleton, we repeated this experiment using a second
antibody recognizing a different epitope on eIF4A1. We observed
a similar pattern of immunfluoresence staining and degree of
colocalization, confirming the colocalization of eIF4A1with F-
actin stress fibers (Figure S1).
Figure 7A represents the staining pattern and localization of
eIF4A1 and paxillin. The colocalization image (Fig. 7B) deter-
mined by the ImageJ plugin was used to compare the degree of
alignment of these two proteins (Fig. 7C). Similar to the results
obtained with F-actin, EC stimulated with HLA class I antibodies
and thrombin exhibited a higher degree of colocalization with
paxillin than cells treated with bFGF or isotype control IgG.
Although the increased alignment of eIF4A1 and paxillin was
more prominent after HLA class I ligation compared to thrombin
(p=0.09), the difference was only statistically significant when
compared to the mIgG (p=0.01) and bFGF (p=0.003) treatment
groups. These results indicate increased colocalization of eIF4A1
with F-actin and paxillin following HLA class I stimulation.
Discussion
The actin cytoskeleton is an important regulator of various
cellular functions in ECs including proliferation, migration and
Figure 3. Directed acyclic graph (DAG) representing the enriched GO categories in the HLA class I stimulated EC cytoskeleton
isolation. The Gene Ontology (GO) enrichment analysis tool called Gene Onology Tree Machine (GOTM) was used to create the DAG. The gene list
was created using the uniprot accession numbers and thus the gene ID type selected was ‘‘hsapiens_uniprot_swissprot_accession.’’ Next the
reference for GOTM was selected as ‘‘hsapiens_genome.’’ The statistical method was set to the default ‘‘hypergeometric,’’ the multiple test
adjustment was set to be done by Benjamini & Hochberg, the significance level was set to the top 10 and the minimum number of genes for a
category was 2. The DAG is a re-creation of the graph generated by GOTM. The shaded boxes indicate categories that were not significantly enriched.
The significantly enriched categories found in the HLA class I treated group are specified by the white boxes and include the adjusted p-values and
the number of proteins found in each category. The categories found to be uniquely enriched only by HLA class I stimulation are indicated in bold.
doi:10.1371/journal.pone.0029472.g003
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underlying HLA class I-mediated actin stress fiber remodeling we
conducted a proteomic analysis of the cytoskeletal fractions of ECs
treated with anti-HLA class I antibodies and contrasted these
findings to thrombin and bFGF-induced cytoskeletal remodeling.
Here we report a novel method to examine the composition of the
EC cytoskeleton and reveal unique cytoskeleton proteomes in ECs
depending on the agonist used for stimulation. Using annotation
tools, a candidate list was created that revealed 12 potential HLA
class I induced targets that may play a role in understanding EC
cytoskeleton changes.
Among the list of candidates, we identified proteins or related
proteins involved in cytoskeleton dynamics. For example, cortactin
is a known actin-binding protein and transduces signaling to the
cytoskeleton [27,28]. It also has the ability to cross-link F-actin,
which is regulated by Src-kinase mediated activation [29].
Additionally, the actin-related protein 2/3 (Arp2/3) complex is
essential in the regulation of actin polymerization and localizes to
sites of dynamic actin [30]. To tie these processes together one
group reported that cortactin colocalizes with both dynamic actin
and the Arp2/3 complex [31]. HLA class I ligation on the surface
of ECs stimulates the formation of actin stress fibers and the
activation of Src family kinases [14]. Thus, it is plausible that HLA
class I-mediated Src kinase phosphorylation may regulate
cortactin binding protein 2 and Arp 2/3 complex subunit 3 in
the formation of stress fibers following class I ligation.
In the past, we established that HLA class I signaling cascades
involve various phosphorylation events and have explored several
key proteins responsible for these events [14,32]. The current data
add to our understanding of these phosphorylation events as we
explored the kinases that have the potential to phosphorylate the
candidate proteins. Among the kinase predictions, cyclin depen-
dent kinase 2 (CDK2 has the potential to phosphorylate 3 of the
candidate proteins. CDK2 has already been established as a
regulator of HLA class I signal transduction. HLA class I ligation
on the surface of ECs leads to the inactivation of retinoblastoma
protein (Rb) and this happens through CDK2 [33]. Rb is negative
regulator of cell cycle progression [34]. Activation of CDK2
relieves the inhibition put forth by Rb and this permits the ECs to
pass the G1 checkpoint and proliferate [33]. The current study
elucidated several candidate targets of CDK2, which may
contribute to a better understanding of the molecular processes
involved in HLA class I-mediated signal transduction leading to
cell proliferation.
Another kinase family predicted to be involved in the
phosphorylation of the candidate proteins is 70-kDa S6 protein
kinase (p70S6k) family, where the specific kinase was ribosomal
protein S6 kinase 1 (S6RP). HLA class I ligation leads to the
phosphorylation of p70S6k and S6RP, which are downstream of
mTOR complex 1 [18]. It has yet to be determined which S6RP
downstream targets are important in HLA class I signaling. The
current findings suggest that S6RP may phosphorylate two of the
candidate proteins, ATP-dependent RNA helicase DDX3X and
nuclear pore complex protein Nup153. DDX3X was confirmed by
Western blot to be associated with the isolated cytoskeleton
fraction following HLA class I ligation on ECs. DDX3X interacts
with TANK binding kinase 1 to activate the interferon (IFN)
promoter. When DDX3X protein levels are reduced using RNAi,
type I IFN production is diminished [35]. Cytokine production is
associated with allograft rejection [36] and in vitro, cytokines are
known to synergize with HLA class I antibodies to enhance signal
transduction [37]. Little is known about the regulation of HLA
class I induced cytokine production and DDX3X may be a
potential target in controlling cytokine induction. Recent findings
suggest that Nup153 is crucial for nucleoskeleton and cytoskeleton
architecture maintenance and is necessary for cell cycle progres-
sion and cell migration. In addition, when Nup 153 is knocked
down by RNAi, there is prominent cytoskeleton rearrangement
Table 1. 12 Candidate Proteins Representing HLA Class I Induced Cytoskeleton Changes.
Accession Protein Name Gene Name GO Categories
Q8WZ74 Cortactin-binding protein 2 CTTNBP2 protein polymerization
cellular protein complex assembly
macromolecular complex assembly
protein complex biogenesis
O15145 Actin-related protein 2/3 complex subunit 3 ARPC3 protein polymerization




Q99880 Histone H2B type 1-L HIST1H2BL macromolecular complex assembly
P83731 60S ribosomal protein L24 RPL24 macromolecular complex assembly
P04114 Apolipoprotein B-100 APOB macromolecular complex assembly
P11142 Heat shock cognate 71 kDa protein HSPA8 hydrolase activity, acting on acid anhydrides
O00571 ATP-dependent RNA helicase DDX3X DDX3X hydrolase activity, acting on acid anhydrides
P60842 Eukaryotic initiation factor 4A-I EIF4A1 hydrolase activity, acting on acid anhydrides
P35249 Replication factor C subunit 4 RFC4 hydrolase activity, acting on acid anhydrides
P49790 Nuclear pore complex protein Nup153 NUP153 hydrolase activity, acting on acid anhydrides
P06576 ATP synthase subunit beta, mitochondrial ATP5B hydrolase activity, acting on acid anhydrides
P67936 Tropomyosin alpha-4 chain TPM4 actin cytoskeleton
doi:10.1371/journal.pone.0029472.t001
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Kinase Family Kinases Candidate Phosphoproteins
ACTR2_ACTR2B_TGFbR2 TGF-beta type II receptor HSPA8, NUP153
Activin receptor type II DDX3X
AMPK AMPK alpha-1 chain RPL24
AMPK alpha-2 chain RPL24
ATM_ATR Serine-protein kinase ATR HSPA8, DDX3X
Serine-protein kinase ATM HSPA8, DDX3X
AuroraA Serine/threonine-protein kinase 6 HIST1H2BL
AuroraC_AuroraB Serine/threonine-protein kinase 12 DDX3X
CaMKIIalpha_CaMKIIdelta CaM-kinase II alpha chain RPL24
CaMKIIbeta_CaMKIIgamma CaM-kinase II gamma chain NUP153
CDK2_CDK3 Cell division protein kinase 2 APOB, EIF4A1, NUP153
CDK4_CDK6 Cell division protein kinase 4 HSPA8
Cell division protein kinase 6 HSPA8
CK2 Casein kinase II, alpha’ chain CTTNBP2, HSPA8, ATP5B, APOB, RPL24,
DDX3X, NUP153
Casein kinase II, alpha chain CTTNBP2, HSPA8, ATP5B, APOB, RPL24,
DDX3X, NUP153
CLK Dual specificity protein kinase CLK1 DDX3X, HIST1H2BL
Dual specificity protein kinase CLK2 DDX3X, HIST1H2BL
DMPK Myotonin-protein kinase RPL24
EGFR Receptor tyrosine-protein kinase erbB-1, erbB-2, erbB-3, erbB-4 HSPA8
EphA7_EphA6_EphA4_EphA3_EphA5 Ephrin type-A receptor 4, 7, 3 DDX3X, TPM4
FLT3_CSF1R_Kit Macrophage colony stimulating factor I receptor ARPC3, DDX3X
Mast/stem cell growth factor receptor ARPC3, DDX3X
GSK3 Glycogen synthase kinase-3 beta HSPA8, DDX3X, NUP153
Glycogen synthase kinase-3 alpha HSPA8, DDX3X, NUP153
InsR Insulin-like growth factor 1 receptor HSPA8, DDX3X, NUP153, TPM4
Insulin receptor HSPA8, DDX3X, NUP153, TPM4
JNK Mitogen-activated protein kinase 8 NUP153
Mitogen-activated protein kinase 10 NUP153
Mitogen-activated protein kinase 9 NUP153
MAP2K6_MAP2K3_MAP2K4_MAP2K7 Dual specificity mitogen-activated protein kinase kinase 4 HSPA8, DDX3X
Dual specificity mitogen-activated protein kinase kinase 3 HSPA8, DDX3X
Dual specificity mitogen-activated protein kinase kinase 6 HSPA8, DDX3X
MAPK3_MAPK1_MAPK7_NLK Mitogen-activated protein kinase 3 NUP153
Mitogen-activated protein kinase 1 NUP153
Mitogen-activated protein kinase 7 NUP153
MAPKAPK MAP kinase-activated protein kinase 5 RPL24
MAP kinase-activated protein kinase 2 RPL24
MAP kinase-activated protein kinase 3 RPL24
Met Hepatocyte growth factor receptor HSPA8
NEK1_NEK5_NEK3_NEK4_NEK11_NEK2 Serine/threonine-protein kinase Nek2 HSPA8, DDX3X, NUP153
p38 Mitogen-activated protein kinase 14 NUP153
Mitogen-activated protein kinase 11 NUP153
Mitogen-activated protein kinase 13 NUP153
p70S6K Ribosomal protein S6 kinase 1 DDX3X, NUP153
PAKA Serine/threonine-protein kinase PAK 1 HSPA8, DDX3X, NUP153
Serine/threonine-protein kinase PAK 2 HSPA8, DDX3X, NUP153
Serine/threonine-protein kinase PAK 3 HSPA8, DDX3X, NUP153
PAKB Serine/threonine-protein kinase PAK 4 DDX3X
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The integrity of the cytoskeleton is key to HLA class I signaling
[14,15] and given the role of Nup153 it seems that this protein
would be worth investigating.
TPM4 was identified as a candidate protein in the HLA class I
treated group by mass spectrometry and confirmed by Western
blot to be present only in the cytoskeleton fraction of HLA class I
stimulated ECs. Tropomyosins are among the most abundant
cytoskeletal proteins in ECs [39]. By mass spectrometry,
tropomyosin-1 was identified as an oxidative-stress-sensitive
phosphoprotein in ECs [40]. H2O2 induced the activation of DAP
kinase, downstream of ERK. DAP kinase promoted the phos-
phorylation of tropomyosin-1, which was essential for H2O2
induced formation of actin stress fibers in ECs [41]. HLA class I
ligation leads to ERK activation [18] and thus, it would be
valuable to determine if TPM4 functions downstream of ERK as
regulator of HLA class I induced cytoskeleton remodeling.
The eIF4A1 protein, functions downstream of mTOR complex
1, which has been shown to phosphorylate 4E-BP1 following class
I ligation [18]. 4E-BP1 is bound to eIF4E and when 4E-BP1
Figure 4. GO categories represented by the 70 kinases. The 70 predicted kinases thought to have the potential to phosphorylate the 11
candidate phosphoproteins were annotated using GOanna and the annotations were categorizied using CateGOrizer which mapped the kinases
based on EGAD2GO. The GO terms mapped to 47 EGAD2GO ancestor terms and this graph represents the top 17 definitions and the rest are grouped
into the ‘‘other’’ category.
doi:10.1371/journal.pone.0029472.g004
Table 2. Cont.
Kinase Family Kinases Candidate Phosphoproteins
Serine/threonine-protein kinase PAK 7 DDX3X
PDGFR Beta platelet-derived growth factor receptor HSPA8
Alpha platelet-derived growth factor receptor HSPA8
Pim2 Serine/threonine-protein kinase Pim-2 RPL24, DDX3X
Pim3_Pim1 Proto-oncogene serine/threonine-protein kinase Pim-1 DDX3X
PKA cAMP-dependent protein kinase, beta-catalytic subunit NUP153
cAMP-dependent protein kinase, alpha-catalytic subunit NUP153
PKC Protein kinase C, delta type HIST1H2BL, NUP153
Protein kinase C, zeta type HIST1H2BL, NUP153
Protein kinase C, iota type HIST1H2BL, NUP153
Protein kinase C, theta type HIST1H2BL, NUP153
Protein kinase C, alpha type HIST1H2BL, NUP153
Protein kinase C, gamma type HIST1H2BL, NUP153
PKD Protein kinase, D1 type HSPA8
Tec Tyrosine-protein kinase ITK/TSK ARPC3
Tyrosine-protein kinase BTK ARPC3
Tyrosine-protein kinase Tec ARPC3
TLK Serine/threonine-protein kinase tousled-like 1 DDX3X, HIST1H2BL
doi:10.1371/journal.pone.0029472.t002
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which includes both eIF4A1 and eIF4G. This complex promotes
translation and cell proliferation [25]. The link between
translational machinery and the cytoskeleton was postulated some
time ago [42]. Continued efforts to make this connection showed
that when the soluble fraction of a cell lysate was compared to the
cytoskeleton fraction, certain initiation factors where enriched in
the cytoskeleton and one of those factors was eIF4A1 [43]. It has
yet to be determined how the cytoskeleton could regulate and
organize translation.
Although eIF4A1 and DDX3X were found by mass spectrom-
etry to be exclusively in the HLA class I treated EC, surprisingly
these proteins were found at approximately equal levels in all of
the treatment groups following cytoskeleton isolation and Western
blotting. The most likely explanation for the detection of eIF4A1
and DDX3X by mass spectrometry only in the class I treated
group is the difference in the sensitivity of these assays. In the ECs
treated with bFGF or thrombin, other more abundant cytoskeletal
proteins may have been present which reduced the relative
amount of DDX3X and eIF4A1, precluding their detection by
mass spectrometry. Indeed, even when highly sensitive mass
spectrometers are used to analyze complex biological samples and
bodily fluids, high-abundance proteins obscure the detection of
lower-abundance proteins [44].
An alternative explanation for these discrepant findings is that
different protein:protein interactions in the treatment groups
influence the ability to detect a protein by mass spectrometry. For
example, the function of eIF4A1 has little to do with its protein
level and more to do with whether or not it is being inhibited [45].
Programmed Cell Death 4 (PDCD4) is a tumor suppressor known
to bind eIF4A1, which inhibits translation initiation and
proliferation [46]. Detection of eIF4A1 in the cytoskeleton of all
treatment groups by Western blot would not be hindered if it is
bound to PDCD4, but detection by mass spectrometry could be
masked.
We found that treatment with HLA class I antibodies or
thrombin stimulated varying degrees of colocalization between
eIF4A1 and F-actin and paxillin suggesting that eIF4A1 may
interact with specific compartments of the cytoskeleton in a unique
manner. Consistent with this concept, recent studies by our
laboratory identified two different signaling pathways leading to
MLC phosphorylation and stress fiber formation in ECs,
depending upon the nature of the stimulus (ME Ziegler,
unpublished). Stimulation with thrombin at 1 U/ml induced a
robust increase in the intracellular Ca
2+ concentration, increased
phosphorylation of MLC and promoted stress fiber formation via
MLCK and ROK in an ERK-independent manner. In contrast,
stimulation of ECs with a low dose of thrombin (1 mU/ml) or
HLA class I antibodies did not promote any detectable change in
intracellular Ca
2+ concentration, but induced MLC phosphoryla-
tion and stress fiber assembly via MLCK and ROK in an ERK1/
2-dependent manner. HLA class I ligation requires the recruit-
ment of integrin ß4 in order to activate proliferation and migration
[47]. In carcinoma migration, a6ß4 integrin functions via its
ability to promote and stabilize F-actin [48]. Additionally,
eukaryotic initiation factors in migrating cells localize with focal
adhesions, which contain actin and this up-regulation of localized
translation is thought to be a result of integrin engagement
[49,50]. These data suggest that the increased colocalization of
eIF4A1 with F-actin and paxillin following class I ligation may be
in response to the HLA class I molecule partnering with integrin
ß4 to elicit intracellular signals. Although the colocalization data
supports a molecular interaction between eIF4A1 and F-actin and
paxillin, additional experiments are required to definitively prove a
physical interaction between these proteins. eIF4A1 was suggested
to be a potential target for developing new anti-cancer and anti-
inflammatory drugs given evidence of cross-talk between transla-
tion and the inflammatory response [51]. Our findings suggest that
eIF4A1 may also be a potential therapeutic target of HLA class I
induced antibody-mediated rejection.
An important functional consequence of HLA class I ligation on
ECs is stimulation of cell proliferation, which we previously
reported to occur in subconfluent ECs [15,52]. To gain knowledge
on the cytoskeleton changes involved in class I-mediated cell
proliferation, we used subconfluent ECs to conduct these
experiments. However, the EC density is an important factor that
influences cellular responses. Confluent ECs regulate thrombosis,
inflammation, vascular cell proliferation and matrix remodeling,
whereas subconfluent ECs promote these events [53]. Cell
morphology, expression of cell surface molecules and behavior
Figure 5. DDX3X, TPM4 and eIF4A1 in the EC cytoskeleton
fraction. (A) The EC cytoskeleton was isolated for the 4 treatment
groups, mIgG 1 mg/ml (lane 1), HLA class I 1 mg/ml (lane 2), thrombin
1 U/ml (lane 3), bFGF 25 ng/ml (lane 4) and ECs that were treated with
cytochalasin D (5 mM, 30 min) (lane 5). The total cell lysate and the
cytoskeleton fraction were subjected to SDS-PAGE separation followed
by Western blot to examine the presence of MLC, DDX3X and TPM4
proteins. (B) The EC cytoskeleton isolation was isolated for the 4
treatment groups, mIgG 1 mg/ml (lane 1), HLA class I 1 mg/ml (lane 2),
thrombin 1 U/ml (lane 3) and bFGF 25 ng/ml (lane 4). The total cell
lysates, the depleted fractions and the cytoskeleton isolated fractions
were subjected to SDS-PAGE separation followed by Western blot to
examine ß-actin, total MLC and eIF4A1 protein levels in the different cell
fractions. (C) The cytoskeleton isolation was performed on ECs treated
with mIgG 1 mg/ml for 10 min (lane 1) or with cytochalasin D (lane 2)
5 mM for 30 min. The total cell lysates, depleted fractions and
cytoskeleton isolated fractions were subjected to SDS-PAGE separation
followed by Western blot to examine eIF4A1, total MLC and ß1-integrin
in the cell fractions. The results presented in panel A and B are
representative of 5 and 3 independent experiments, respectively.
doi:10.1371/journal.pone.0029472.g005
Characterization of Endothelial Cell Cytoskeleton
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e29472of the ECs differ in subconfluent versus confluent ECs [54].
Additionally, the EC response to an agonist varies depending on
cell density [55,56]. A quiescent EC monolayer is more similar to
the in vivo setting in appearance and differentiated properties
[57,58]. We have yet to explore the cytoskeletal proteome of a
confluent monolayer of ECs in response to HLA class I ligation
and postulate that a confluent monolayer may respond differently
and utilize distinct signaling pathways.
A key question is how signal transduction is orchestrated
through these molecular interactions to stimulate actin cytoskeletal
remodeling. Our previous publications and current data are
consistent with a model whereby molecular aggregation of HLA
class I molecules with antibodies leads to recruitment of integrin
ß4 and the subsequent activation of intracellular signals that
increase Rho-GTP activity, induce phosphorylation of ROK and
trigger the assembly and phosphorylation of FAK, Src and paxillin
at the focal adhesions to stimulate actin reorganization
[13,14,15,47]. The new candidate proteins identified in this study
may further contribute to this model. Candidates such as TPM4,
eIF4A1, DDX3X, cortactin binding protein 2 and Arp2/3 may be
recruited to the focal adhesions to regulate cell proliferation and
survival. Similar signaling cascades have been described following
antibody cross-linking of ICAM-1 on ECs. ICAM-1 ligation
induced cytoskeleton changes, which included increased intracel-
lular calcium, protein kinase C activation, phosphorylation of
cortactin and other actin-binding proteins by Src, activation of
RhoA GTPase, and subsequent rearrangements of the actin
[59,60,61,62,63].
In conclusion, these studies provide new information that can be
applied to the exploration of known pathways. Given that
phosphoprotein signal transduction is essential to HLA class I
EC activation, not only are the proteins relevant, but also their
corresponding kinases. Thus, validation of these proteins and
examination of their activation state will be important in future
Figure 6. Colocalization of eIF4A1 and F-actin. (A) The localization of eIF4A1 and F-actin in the EC was determined by confocal microscopy. Cell
were treated and prepared for staining and microscopy. The scale bar is equal to 10 mm. Data is representative of 4 independent experiments. (B)
eIF4A1 and F-actin colocalization was determined by the the ImageJ plugin Colocalization Finder (http://rsbweb.nih.gov/ij/plugins/colocalization-
finder.html). Manders’ Overlay coefficients were 0.916 (mIgG), 0.926 (HLA class I), 0.942 (thrombin) and 0.921 (bFGF). The data represents 4
independent experiments. (C) Intensities of the colocalization of 3 images per group were determined for each independent experiment (Avg 6 SD):
mIgG (3.861.7), HLA class I (15.962.3), thrombin (6.463.2) and bFGF (1.960.9). The colocalization intensity of eIF4A1 and F-actin in the HLA class I
treated group was significantly increased compared to the unstimulated and bFGF groups; mIgG (p=0.006), thrombin (p=0.07) and bFGF (p=0.002)
as determined by student t-test.
doi:10.1371/journal.pone.0029472.g006
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understanding the mechanisms of HLA class I induced antibody-
mediated rejection. Additionally, these methods can be applied to
other cell types and agonists as an effort to understand the role of
cytoskeleton changes in many pathways.
Supporting Information
Figure S1 Validation of eIF4A1 localization. The localiza-
tion of eIF4A1 and F-actin by confocal microscopy in ECs treated
with (A) mIgG (1 mg/ml), (B) and HLA class I antibody (1 mg/ml)
was performed using the eIF4A1 antibody used in Figure 6 (eIF4A1
Ab 1) and an additional antibody, which recognizes a different
epitope of eIF4A1 (eIF4A1 Ab 2). A high-resolution image of an
individual EC is shown for each antibody. The scale bar is equal to
1 mm. (C) The localization of eIF4A1 and F-actin for the 2 eIF4A1
antibodiesshowingmultipleECsineachfield.The scalebarisequal
to 10 mm. (D) The colocalization of eIF4A1 and F-actin was
determined by the ImageJ plugin, Colocalization Finder. The
Manders’ Overlay coefficients for the experiment using eIF4A1 Ab
1 were 0.934 (mIgG) and 0.918 (HLA class I). Intensities of the
colocalization of 3 images per group were determined (Avg 6 SD):
mIgG (4.260.35) and HLA class I (17.862.0). The colocalization
intensity of eIF4A1 Ab 1 and F-actin in the HLA class I treated
group was significantly increased compared to the unstimulated
p=0.004 as determined by student t-test. The Manders’ Overlay
coefficients for the experiment using eIF4A1 Ab 2 were 0.914
(mIgG) and 0.933 (HLA class I). Intensities of the colocalization of 3
images per group were determined (Avg 6 SD): mIgG (5.360.85)
and HLA class I (19.163.2). The colocalization intensity of the
eIF4A1 Ab 2 and F-actin in the HLA class I treated group was
significantly increased compared to the unstimulated p=0.01 as
determined by student t-test.
(PPTX)
Table S1 Identity of Proteins in the Cytoskeleton
Preparations of Each Treatment Group. To identify the
proteins in the cytoskeleton isolation preparations, nLC-MS/MS
was performed on the peptides and Mascot searches were carried
out. A total of 128 cytoskeleton-associated proteins were identified
Figure 7. Colocalization of eIF4A1 and Paxillin. (A) The localization of eIF4A1 and paxillin in the EC was determined by confocal microscopy.
Cell were treated and prepared for staining and microscopy. The scale bar is equal to 10 mm. Data is representative of 4 independent experiments. (B)
eIF4A1 and paxillin colocalization was determined by the ImageJ plugin Colocalization Finder. Mander’s Overlap coefficients were 0.977 (mIgG), 0.929
(HLA class I), 0.933 (thrombin) and 0.888 (bFGF). The data represents 4 independent experiments. (C) Intensities of the colocalization of 3 images per
group were determined for each independent experiment (Avg 6 SD): mIgG (14.364.3), HLA class I (30.264.1), thrombin (19.167.8) and bFGF
(11.763.0). The colocalization intensity of eIF4A1 and paxillin in the HLA class I treated group was significantly increased compared to the
unstimulated and bFGF groups; mIgG (p=0.01), thrombin (p=0.09) and bFGF (p=0.003) as determined by student t-test.
doi:10.1371/journal.pone.0029472.g007
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thrombin treated ECs and 88 in bFGF treated ECs.
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